In breast cancer, PAI-1 together with uPA, have been convincingly shown to be strong prognostic markers, have recently reached “level-of-evidence 1” and are recommended in clinical use as a stratification parameter for treatment of node-negative breast cancer [41]. Here, PLAU is linked to breast carcinoma.